Patents Assigned to I.D.M. Immuno-Designed Molecules
-
Patent number: 7252996Abstract: The invention consists in the use of a maturation agent comprising a mixture of ribosomal and/or membrane fractions for the preparation of mature dendritic cells from immature dendritic cells.Type: GrantFiled: December 29, 2001Date of Patent: August 7, 2007Assignee: I.D.M. Immuno-Designed MoleculesInventors: Claire Boccaccio, Alessandra Nardin, Jean-Pierre Abastado
-
Patent number: 6881413Abstract: The invention relates to humanized biomaterial comprising a porous biocompatible composite material customized and implanted with monocyte derived cells preferably with macrophages.Type: GrantFiled: August 22, 2000Date of Patent: April 19, 2005Assignee: I.D.M. Immuno-Designed MoleculesInventor: Jacques Bartholeyns
-
Publication number: 20050048039Abstract: Method for the treatment or diagnosis of pathologies either expressed in injured or pathological multiple sites in tissues or in the body or expressed in injured or pathological sites of tissues or cells in sites of the body, which are difficult to access, with said sites or areas in immediate proximity to said sites being the source of the release of chemotactic factors for endogenous macrophages, either spontaneously or upon suitable stimulation, wherein said treatment is carried out by administration to the body of an appropriate amount of exogenous monocyte derived cells, said monocyte derived cells being, in the case of treatment, loaded with corrective agents with respect to the pathologies to be treated, and with said monocyte derived cells having the properties of mobilisation towards the source of the above-said released chemotactic factors and in target the cells present in the vicinity of the said released chemotactic factors, and in the case of diagnosis, loaded with a marker enabling the detectioType: ApplicationFiled: January 30, 2004Publication date: March 3, 2005Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.M), I.D.M. IMMUNO-DESIGNED MOLECULESInventors: Patrick Dreyfus, Elaine Parrish, Luis Garcia, Mohamed Chokri, Jacques Bartholeyns, Elise Peltekian
-
Patent number: 6821516Abstract: The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-&ggr; is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-&ggr; is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-&ggr; is in a ratio such that after 60h of activation with IFN-&ggr;, the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-&ggr; activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.Type: GrantFiled: May 4, 1999Date of Patent: November 23, 2004Assignee: I.D.M. Immuno-Designed MoleculesInventors: Mohamed Chokri, Jacques Bartholeyns
-
Patent number: 6737051Abstract: The invention relates to a cell composition containing macrophages, presenting anti-infectious and hematopoietic properties. More particularly, the invention relates to a cell composition containing macrophages, myeloid cells and progenitors; said cell compositions are useful for the restoration of hematopoiesis in an aplasic patient and/or the protection of patients against infectious diseases or against residual tumors.Type: GrantFiled: November 27, 2001Date of Patent: May 18, 2004Assignees: I.D.M. Immuno-Designed Molecules, Centre Hospitalier Universitaire de MontpellierInventors: Bernard Klein, Zhao Yang Lu, Jacques Bartholeyns
-
Patent number: 6713056Abstract: The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts: monocyte derived cells, particularly cytotoxic macrophages, chemotherapy or immunotherapy drugs, for the simultaneous, separate or sequential use, for the treatment of cancer or infectious diseases.Type: GrantFiled: November 29, 2000Date of Patent: March 30, 2004Assignee: I.D.M. Immuno-Designed MoleculesInventors: Jacques Bartholeyns, Yves Fouron, Jean-Loup Romet-Lemonne
-
Publication number: 20040018184Abstract: The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts:Type: ApplicationFiled: July 21, 2003Publication date: January 29, 2004Applicant: I.D.M. IMMUNO-DESIGNED MOLECULESInventors: Jacques Bartholeyns, Yves Fouron, Jean-Loup Romet-Lemonne
-
Patent number: 6616925Abstract: The present invention relates to combined preparation containing as active substance the following individual components, in the form of a kit-of-parts: monocyte derived cells, particularly cytotoxic macrophages, chemotherapy or immunotherapy drugs, for the simultaneous, separate or sequential use, for the treatment of cancer or infectious diseases.Type: GrantFiled: May 19, 1998Date of Patent: September 9, 2003Assignee: I.D.M. Immuno-Designed MoleculesInventors: Jacques Bartholeyns, Yves Fouron, Jean-Loup Romet-Lemonne
-
Patent number: 6596275Abstract: Monocyte derived cells with immunosuppressive properties including an increase in at least one of the following PGE-2, IL-10 and IL-4. Monocyte derived cells with a decreased level of expression and secretion of inflammatory and immunostimulating cytokines and a decrease on the membrane of activation or accessory molecules in the presence of polylysine-cDNA in the nucleus of the monocyte derived cells.Type: GrantFiled: October 2, 2000Date of Patent: July 22, 2003Assignee: I.D.M. Immuno-Designed MoleculesInventors: Jacques Bartholeyns, Mohamed Chokri, Jean-Loup Romet-Lemonne
-
Publication number: 20030108534Abstract: The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-&ggr; is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-&ggr; is increased by about 20 to 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-&ggr; is in a ratio such that after 60 h of activation with IFN-&ggr;, the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-&ggr; activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.Type: ApplicationFiled: January 6, 2003Publication date: June 12, 2003Applicant: I.D.M. Immuno-Designed MoleculesInventors: Mohamed Chokri, Jacques Bartholeyns
-
Patent number: 6540994Abstract: The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-7 is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-&ggr; is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-&ggr; is in a ratio such that after 60h of activation with IFN-&ggr;, the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-&ggr; activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.Type: GrantFiled: May 4, 1999Date of Patent: April 1, 2003Assignee: I.D.M. Immuno-Designed MoleculesInventors: Mohamed Chokri, Jacques Bartholeyns
-
Patent number: 6372499Abstract: The complex has at least one negatively charged nucleic acid bonded to at least one positively charged polymeric conjugate The conjugate containing a polylysine formed from monomers having free NH3+ groups, and having at least 10% of the free NH3+ groups substituted by residues which can be protonated in a weakly acid medium causing destabilization of cell membranes. Optionally, some of the free NH3+ groups can be substituted by a molecule with a recognition signal by a cell membrane receptor. The free NH3+ groups of the said polylysine make up at least 30% of the monomers of the polymeric conjugate. The residue that causes the destabilization of cell membrane in weak acid of quinolines of the formula: where R1 is hydrogen, R2 is —(CH2)n13 CO2—H, X is hydrogen or chlorine and n is an integer from 1 to 10. The signal is a simple oside or a disaccharide or peptide.Type: GrantFiled: May 3, 1999Date of Patent: April 16, 2002Assignee: I.D.M. Immuno-Designed MoleculesInventors: Patrick Midoux, Michel Monsigny
-
Patent number: 6251858Abstract: The invention relates to compounds comprising one or several oligosides, each of said oligosides being fixed in a covalent manner on one or many molecules, matrixs or particles, specifically one, two or three, via an intermediary molecule possessing a nitrogen atom carried by a carbon in &agr; of a C═O group and one or many functional groups, specifically one, two or three, the covalent bond between said intermediary molecule and the oligoside being done by the intermediary of said nitrogen atom, and the covalent bond between said intermediary molecule and said molecule, said matrix, said particle, or said molecules, said matrixs, said particles being done by the intermediary of the said functional groups of said intermediary molecule and appropriate functional groups to the molecule(s), the matrix(ces) or the particle(s).Type: GrantFiled: February 21, 1996Date of Patent: June 26, 2001Assignee: I.D.M. Immuno-Designed MoleculesInventors: Michel Monsigny, Annie-Claude Roche, Nadia Sdiqui, Roger Mayer
-
Patent number: 6221576Abstract: The invention relates to a process for preparing a composition comprising macrophages, optionally activated, and/or cells derived from-monocytes with a strong potential for antigen presentation, said process comprising a stage of culture of monocytes present in the starting composition, this stage being preceding and/or followed by a stage of elimination of all or part of the constituents other than the monocytes present in the starting composition, with the aid of antibodies directed against said constituents, and/or followed by a stage of elutriation. The invention also concerns the compositions of kits of reducing this process to practice.Type: GrantFiled: September 23, 1999Date of Patent: April 24, 2001Assignee: I. D. M. Immuno-Designed MoleculesInventors: Jean-Loup Romet-Lemonne, Mohamed Chokri
-
Patent number: 6140122Abstract: The invention relates to a process for preparing a composition comprising macrophages, optionally activated, and/or cells derived from monocytes with a strong potential for antigen presentation, said process comprising a stage of culture of monocytes present in the starting composition, this stage being preceding and/or followed by a stage of elimination of all or part of the constituents other than the monocytes present in the starting composition, with the aid of antibodies directed against said constituents, and/or followed by a stage of elutriation. The invention also concerns the compositions of kits for reducing this process to practice.Type: GrantFiled: February 18, 1998Date of Patent: October 31, 2000Assignee: I.D.M. Immuno-Designed MoleculesInventors: Jean-Loup Romet-Lemonne, Mohamed Chokri
-
Patent number: 6051432Abstract: The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-.gamma. is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-.gamma. is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-.gamma. is in a ratio such that after 60 h of activation with IFN-.gamma., the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-.gamma. activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.Type: GrantFiled: September 22, 1999Date of Patent: April 18, 2000Assignee: I.D.M. Immuno-Designed MoleculesInventors: Mohamed Chokri, Jacques Bartholeyns
-
Patent number: 6001351Abstract: The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-.gamma. is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity with IFN-.gamma. is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%; the extension of the deactivation of the cytotoxic activity in reply to an activation of IFN-.gamma. is in a ratio such that after 60 h of activation with IFN-.gamma., the cytotoxic activity is higher than or equal to 30%, preferably of about 55%, compared to the maximum cytotoxic activity presented by the macrophages due to IFN-.gamma. activation, with said cytotoxic activity being measured as the percentage of inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.Type: GrantFiled: July 18, 1997Date of Patent: December 14, 1999Assignee: I.D.M. Immuno-Designed MoleculesInventors: Mohamed Chokri, Jacques Bartholeyns
-
Patent number: 5804442Abstract: The invention relates to a process for preparing a composition comprising macrophages, optionally activated, and/or cells derived from monocytes with a strong potential for antigen presentation, said process comprising a stage of culture of monocytes present in the starting composition, this stage being preceding and/or followed by a stage of elimination of all or part of the constituents other than the monocytes present in the starting composition, with the aid of antibodies directed against said constituents, and/or followed by a stage of elutriation. The invention also concerns the compositions of kits for reducing this process to practice.Type: GrantFiled: May 28, 1996Date of Patent: September 8, 1998Assignee: I.D.M. Immuno-Designed MoleculesInventors: Jean-Loup Romet-Lemonne, Mohamed Chokri
-
Patent number: 5733762Abstract: A compound consisting essentially of polylysine conjugated to non-charged residues and recognition signals wherein the free amino functions of said polylysine are substituted with non-charged residues and said recognition signals, which non-charged residues consist of gluconalactone and which recognition signals are at least one member of the group consisting of galactoside, mannoside, fucoside, Lewis.sup.x, Lewis.sup.b, oligomannoside, oligolactosamine saccharides and peptide ANP and said conjugated polylysine contains at least 30% unsubstituted free amino functions and a method of transfecting cultured cells.Type: GrantFiled: October 31, 1996Date of Patent: March 31, 1998Assignee: I.D.M. Immuno-Designed MoleculesInventors: Patrick Midoux, Patrick Erbacher, Annie-Claude Roche-Degremont, Michel Monsigny
-
Patent number: 5662899Abstract: Macrophages have been developed, which possess at least one of the following properties:their cytotoxic activity without IFN-.gamma. is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%;their cytotoxic activity with IFN-.gamma. is increased by about 20 to about 40% with respect to standard macrophages, and is preferably of about 93%;deactivation of the cytotoxic activity following activation of IFN-.gamma. is such that sixty hours after activation with IFN-.gamma., the residual cytotoxic activity is at least 30%, preferably about 55%, of the maximum cytotoxic activity presented by the macrophages due to IFN-.gamma. activation, with said cytotoxic activity being measured as a percentage of the inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells. The macrophages are prepared by culturing healthy human monocytes and lymphocytes in a culture medium containing 1,25-dihydroxy vitamin D.sub.3 and GM-CSF.Type: GrantFiled: January 17, 1995Date of Patent: September 2, 1997Assignee: I.D.M. Immuno-Designed MoleculesInventors: Mohamed Chokri, Jacques Bartholeyns